A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity in patients with post-herpetic neuralgia (EMPHENE).

Project: Research

StatusActive
Effective start/end date28/11/1828/11/20